首页> 美国卫生研究院文献>BMJ Open Access >Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised double-blind placebo-controlled trial (RAJ4) in Japan

【2h】

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised double-blind placebo-controlled trial (RAJ4) in Japan

机译：培非替尼（ASP015K）在类风湿关节炎和甲氨蝶呤反应不充分的患者中的疗效和安全性：日本一项III期随机双盲安慰剂对照试验（RAJ4）的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

ObjectiveTo evaluate the efficacy and safety of the oral Janus kinase (JAK) inhibitor peficitinib versus placebo in Japanese patients with rheumatoid arthritis (RA).

机译：目的评估口服Janus激酶（JAK）抑制剂培非替尼与安慰剂在日本类风湿关节炎（RA）患者中的疗效和安全性。

著录项

期刊名称 BMJ Open Access
作者
Tsutomu Takeuchi; Yoshiya Tanaka; Sakae Tanaka; Atsushi Kawakami; Manabu Iwasaki; Kou Katayama; Mitsuhiro Rokuda; Hiroyuki Izutsu; Satoshi Ushijima; Yuichiro Kaneko; Teruaki Shiomi; Emi Yamada; Désirée van der Heijde;
展开▼
作者单位

展开▼
年(卷),期 -1(78),10
年度 -1
页码 1305–1319
总页数 15
原文格式 PDF
正文语种
中图分类
关键词
rheumatoid arthritis DAS28 disease activity methotrexate treatment;

机译：类风湿关节炎;DAS28;疾病活动;甲氨蝶呤;治疗;

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan [J] . Takeuchi Tsutomu, Tanaka Yoshiya, Tanaka Sakae, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2019,第10期

机译：PEFICITINIB（ASP015K）在类风湿性关节炎患者中的疗效和安全性和对甲氨蝶呤的不足：日本III期随机，双盲，安慰剂对照试验（RAJ4）的结果
2. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3) [J] . Tanaka Yoshiya, Takeuchi Tsutomu, Tanaka Sakae, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2019,第10期

机译：PEFICITINIB（ASP015K）对类风湿性关节炎患者的疗效和安全性和对常规DMARD的反应不足：随机，双盲，安慰剂对照期III试验（RAJ3）
3. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study [J] . Takeuchi Tsutomu, Tanaka Yoshiya, Iwasaki Manabu, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2016,第6期

机译：口服Janus激酶抑制剂培非替尼（ASP015K）单一疗法在日本中重度类风湿关节炎患者中的疗效和安全性：一项为期12周，随机，双盲，安慰剂对照的IIb期研究
4. A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil (Eicosapentaenoic Acid and Docosahexaenoic Acid) on Lung and Systemic Inflammation in Patients with Acute Lung Injury. [D] . Stapleton, Renee Doney. 2010

机译：鱼油（二十碳五烯酸和二十二碳六烯酸）对急性肺损伤患者的肺和全身炎症的II期，随机，双盲，安慰剂对照试验。
5. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised double-blind placebo-controlled phase III trial (RAJ3) [O] . Yoshiya Tanaka, Tsutomu Takeuchi, Sakae Tanaka, -1

机译：培非替尼（ASP015K）在类风湿关节炎和对常规DMARD反应不足的患者中的疗效和安全性：一项随机双盲安慰剂对照的III期临床试验（RAJ3）
6. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan [O] . Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, 2019

机译：PEFICITINIB（ASP015K）对类风湿性关节炎患者的疗效和安全性和对甲氨蝶呤的不足：日本III期随机，双盲，安慰剂对照试验（RAJ4）的结果

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised double-blind placebo-controlled trial (RAJ4) in Japan

摘要

著录项

相似文献

相关主题

期刊订阅